• Lukas Goertz, Franziska Dorn, Bastian Kraus, Jan Borggrefe, Robert Forbrig, Marc Schlamann, Thomas Liebig, Bernd Turowski, and Christoph Kabbasch.
• Center for Neurosurgery, University Hospital of Cologne, Cologne, Germany. Electronic address: lukas.goertz@uk-koeln.de.
• World Neurosurg. 2019 Jun 1; 126: e1503-e1509.

ObjectiveThe Derivo Embolization Device (DED) is a novel flow-diverter stent consisting of a flexible structure and a surface modification that aims to reduce thrombogenicity. Here, we report 1-year clinical and angiographic follow-up results of the second-generation DED for the treatment of intracranial aneurysms.MethodsThis is a retrospective study of 59 consecutive patients (mean age: 53 years, 81% women) treated with the DED for 59 aneurysms (mean size: 8.1 mm) between November 2015 and February 2018 at 3 German tertiary care centers. We evaluated the rate of ischemic stroke, functional outcome, and angiographic results during a 1-year follow-up period.ResultsDeployment of the DED was successful in all cases. Adverse events were observed in 6 procedures (10.2%), of which 2 were symptomatic (3.4%). No delayed ischemic or hemorrhagic events occurred during the 1-year follow-up and there were no deaths. Permanent morbidity due to in-stent thrombosis and consecutive ischemic stroke occurred in 1 patient (1.7%). Complete (O'Kelly-Marotta grading scale D) and favorable (O'Kelly-Marotta grading scale C+D) aneurysm occlusion was obtained in 70.5% (31/44) and 88.7% (39/44) at 6 months and 82.8% (24/29) and 100% (29/29) at 12 months, respectively.ConclusionsOur results demonstrate that treatment of intracranial aneurysms with the DED is associated with low rates of ischemic complications and adequate aneurysm occlusion at 1-year follow-up.Copyright © 2019 Elsevier Inc. All rights reserved.

5 keywords...

hide…